Effects of celiprolol on systemic and forearm circulation in hypertensive patients: a double-blind cross-over study versus metoprolol.
The antihypertensive efficacy of a new beta-receptor blocking agent, celiprolol, was compared with that of a well-established antihypertensive drug, metoprolol. Their systemic and forearm hemodynamic effects were investigated using echocardiography and two-dimensional pulsed Doppler flowmetry, respectively. Twenty hypertensive patients completed a double-blind, cross-over, randomized study using celiprolol and metoprolol. Two six-week courses with celiprolol or metoprolol were preceded and followed by a two-week placebo period; the total duration of the study was 18 weeks. In spite of a comparable efficacy in reducing systolic and diastolic blood pressure (about 10% of the basal value), the two drugs showed quite different systemic and regional hemodynamic effects. Celiprolol induced a significant decrease in forearm vascular resistance (from 157 +/- 17 to 113 +/- 13 mm Hg/mL/s, P less than .01) and total peripheral resistance (from 1596 +/- 90 to 1398 +/- 91 dyne.s.cm-5, P less than .05) whereas cardiac output remained unchanged and forearm blood flow increased. Metoprolol reduced cardiac output (from 6.5 +/- 3 to 5.7 +/- 3 L/min, P less than .05), through a reduction in heart rate, since stroke volume was unchanged. Both drugs did not significantly modify cardiac performance, as evaluated by left ventricle fractional shortening and ejection fraction. Thus, the two drugs seem to reduce blood pressure through different hemodynamic mechanisms.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000494:pharmacology*; D000328:Adult; D017272:Celiprolol; D004311:Double-Blind Method; D004452:Echocardiography; D005260:Female; D005542:Forearm / Q000098:blood supply; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000503:physiopathology*; D008297:Male; D008790:Metoprolol / Q000494:pharmacology*; D008875:Middle Aged; D010431:Pentoxifylline / Q000627:therapeutic use*; D011412:Propanolamines / Q000009:adverse effects / Q000494:pharmacology*; D012039:Regional Blood Flow / Q000187:drug effects; D013805:Theobromine / Q000031:analogs & derivatives*; D014463:Ultrasonography
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D017272:Celiprolol; D008790:Metoprolol; D013805:Theobromine; D010431:Pentoxifylline